May 15th 2024
“The association of lower testosterone concentrations with higher all-cause mortality was present irrespective of luteinizing hormone concentrations, indicating that low testosterone was the main factor," says Bu B. Yeap, MBBS, FRACP, PhD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Man's best friend may also help detect prostate cancer
May 19th 2014It is hard to imagine a world without dogs. Since the beginning of civilization, from hunting to herding, dogs have literally been man's best friend. Now, canines are being enlisted to help with a major health problem of the modern age: prostate cancer detection.
Targeted MRI biopsy more likely to find high-grade prostate cancer
May 19th 2014Targeted biopsy locations using cognitive magnetic resonance imaging targeting were more than twice as likely to show prostate cancer compared with transrectal ultrasound template biopsy, and cancers in these locations were twice as likely to be high grade, researchers from Washington University, St. Louis reported yesterday.
Androgen inhibitor shows meaningful benefit pre-chemo
May 18th 2014Data from the final analysis of the international, phase III PREVAIL study show that enzalutamide (XTANDI) added to androgen deprivation therapy at the time of progression provides meaningful clinical benefit for men with chemotherapy-naïve metastatic castrate-resistant prostate cancer, including those with visceral disease.
Effects of PDE-5 inhibitors, active surveillance among localized prostate cancer topics
May 7th 2014Studies examining the post-prostatectomy effects of phosphodiesterase type-5 inhibitors and those discussing active surveillance are among the key papers in localized prostate cancer to be presented at this year's AUA annual meeting, according to Leonard G. Gomella, MD.
Vitamin D deficiency may raise aggressive prostate cancer odds
May 5th 2014African-American and European-American men at high risk of prostate cancer have greater odds of being diagnosed with an aggressive form of the disease if they have vitamin D deficiency, researchers from Chicago’s Northwestern Medicine and the University of Illinois at Chicago reported in a recently published study.
Convective heat system shows efficacy in treating BPH
April 25th 2014Analyses of serial magnetic resonance imaging and three-dimensional renderings of those images provide proof of principle for using convective thermal heating to ablate prostate tissue, and early evidence suggests the efficacy and potential clinical advantages of using this novel technology to treat BPH, said first author Lance A. Mynderse, MD, at the European Association of Urology annual congress in Stockholm, Sweden.
Peyronie’s treatment shows efficacy in phase III studies
April 23rd 2014Intralesional injection of collagenase clostridium histolyticum (CCH [XIAFLEX]) improves the physical and psychological aspects of Peyronie’s disease in men regardless of erectile dysfunction severity and whether they have a history of prior treatment or prostatectomy, according to a recent study.
Focal therapy: Magic bullet or unproven treatment?
April 23rd 2014Focal therapy has been promoted as a minimally morbid option for men with localized low-risk prostate cancer who nevertheless want their disease treated. Opponents of focal therapy note the heterogeneity and multifocal nature of prostate cancer, the difficulty of accurately targeting and destroying an index tumor with focal therapy, and the unknown biologic potential of the tumor.
Robotic vs. open RP: Equivocal results (again)
April 21st 2014A new study has found that for men 65 years of age and older, robot-assisted radical prostatectomy and open prostatectomy have similar rates of complications, providing further evidence that outcomes between the two procedures are not significantly different.
Testosterone safety, efficacy data on Peyronie's treatment among sexual dysfunction research
April 17th 2014The safety of testosterone replacement therapy has been the subject of two recently published studies, which were followed by a January 2014 FDA announcement that the agency is investigating the risk of stroke, heart attack, and death in men taking TRT. Additional data on the safety of TRT, including its use in men following radical prostatectomy, will be presented at the AUA meeting, said John J. Mulcahy, MD, PhD.
Advanced prostate cancer research focuses on newer agents for mCRPC
April 17th 2014Research in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer, including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).
Infertility research explores linkage to all-cause mortality, psychiatric disorders
April 17th 2014A number of studies at the 2014 AUA annual meeting will indicate that male infertility is a harbinger of other diseases, specifically suggesting “linkage to all-cause mortality, psychiatric disorders, morbidity, and offspring birth defect risk,” said James M. Hotaling, MD, assistant professor of surgery in the division of urology at the University of Utah, Salt Lake City.
Urology Product Preview April 2014
April 16th 2014Drugs and devices in the pipeline from Astellas Pharma, Medivation, Repros Therapeutics, Metamark Genetics, Argos Therapeutics, S1 Biopharma, Ipsen, Sprout Pharmaceuticals, Antigen Express, Generex Biotechnology, Veloxis Pharmaceuticals, and Absorption Pharmaceuticals.